FDA approves first vaccine for RSV, a moment six decades in the
WEBMay 3, 2023 · CNN — After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV – and more are on the way. On Wednesday, the US Food and Drug...
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of...
CDC Updates RSV Vaccination Recommendation for Adults
WEBJun 26, 2024 · Today, CDC updated its recommendation for the use of Respiratory Syncytial Virus (RSV) vaccines in people ages 60 and older. For this upcoming respiratory virus season, CDC recommends: Everyone …
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ...
WEBApr 9, 2024 · ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk. The vaccine was well-tolerated and demonstrated an immune response non-inferior to adults aged 60 years and older
FDA Approves First Vaccine for Pregnant Individuals to Prevent …
WEBAug 22, 2023 · Today, the U.S. Food and Drug Administration approved Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use in pregnant individuals to prevent lower respiratory...
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
WEBMay 31, 2024 · mRESVIA (Respiratory Syncytial Virus Vaccine) is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.
New Monoclonal Antibody and Vaccine Can Protect Kids from RSV
WEBSep 25, 2023 · Nirsevimab (brand name: Beyfortus™) and Abrysvo™, a vaccine given to pregnant women are new preventive options for respiratory syncytial virus (RSV) that could help keep vulnerable infants and toddlers out of the hospital this year. Yale Medicine experts tell you what you need to know.
Use of Respiratory Syncytial Virus Vaccines for Adults ...
WEBAug 15, 2024 · On June 21, 2023, the Advisory Committee on Immunization Practices (ACIP) recommended that adults aged ≥60 years may receive a single dose of respiratory syncytial virus (RSV) vaccine, using shared clinical decision-making.
‘A good day’: FDA approves world’s first RSV vaccine - Nature
WEBMay 3, 2023 · The US Food and Drug Administration (FDA) has approved GSK’s vaccine against respiratory syncytial virus (RSV) for use in people aged 60 years and older. This is the first RSV vaccine to...
Progress at last against RSV - Nature Medicine
WEBSep 14, 2023 · A surge in respiratory syncytial virus (RSV) infections and RSV-related hospitalizations in the 2023 Southern Hemisphere winter, similar to that seen in 2022 in northern climes, has...